Pfizer Inc.
π¨ Critical Risk
FEI: 2416101 β’ New York, NY β’ UNITED STATES
FEI Number
2416101
Location
New York, NY
Country
UNITED STATESAddress
235 East 42nd Street, , New York, NY, United States
Critical Risk
FDA Import Risk Assessment
This firm has an extensive history of FDA import refusals with severe violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity β AI-assessed (1-10)
- 30% Refusal Volume β Logarithmic scale
- 20% Recency β Decays over 5 years
- 10% Frequency β Refusals per year
Β© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
AGR RX
The article appears to be a prescription drug manufactured in the U.S. and offered for import by other than the manufacturer and reimportation does not appear to have been authorized by the Secretary for use in a medical emergency.
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
NEW VET DR
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.
DRUG GMPS
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 12/15/2025 | 58HCY05SOMATROPIN | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/24/2025 | 66MDA03ALPRAZOLAM (TRANQUILIZER) | Division of Northeast Imports (DNEI) | |
| 10/28/2024 | 61LCB44APIXABAN (ANTI-COAGULANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/22/2024 | 61WCY59VORICONAZOLE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/28/2024 | 66SDL45ALPROSTADIL (VASODILATOR) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/16/2023 | 66MCY86LORAZEPAM (TRANQUILIZER) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/18/2023 | 64GCY07ESTRADIOL (ESTROGEN) | Division of Southeast Imports (DSEI) | |
| 3/22/2023 | 56CDK70CEFTRIAXONE SODIUM (CEPHALOSPORINS) | 179AGR RX | Division of West Coast Imports (DWCI) |
| 1/30/2023 | 66VDY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/30/2022 | 62TDY07PANTOPRAZOLE SODIUM | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/30/2022 | 64BDY37SPIRONOLACTONE (DIURETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/3/2022 | 65JDC21MEDROXYPROGESTERONE ACETATE (PROGESTIN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/22/2022 | 61NDB84DESVENLAFAXINE SUCCINATE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/31/2022 | 56ECA65OXYTETRACYCLINE (TETRACYCLINES) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/10/2022 | 66FDA99SUPPRESSANT N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/17/2021 | 64RCY21SOMATROPIN (HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/22/2021 | 56ICY76AZITHROMYCIN (MACAROLIDES) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/15/2021 | 61NCA65CITALOPRAM HYDROBROMIDE (ANTI-DEPRESSANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/15/2021 | 64BCA37SPIRONOLACTONE (DIURETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/9/2021 | 61NCB69GABAPENTIN (ANTI-DEPRESSANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/28/2021 | 62OCY14AMLODIPINE BESYLATE (ANTI-HYPERTENSIVE, PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/19/2020 | 65QDA99RELAXANT N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/20/2020 | 56IBA76AZITHROMYCIN (MACAROLIDES) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/18/2020 | 64BCA37SPIRONOLACTONE (DIURETIC) | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 4/27/2020 | 65PCL02SILDENAFIL CITRATE (REGULATOR) | Division of Northern Border Imports (DNBI) | |
| 11/26/2019 | 65KDL08LATANOPROST (PROSTAGLANDIN) | 27DRUG GMPS | Division of Southeast Imports (DSEI) |
| 10/31/2019 | 56YCA99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/21/2019 | 66VDA99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/21/2019 | 66VDA99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/21/2019 | 66VDA99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/5/2018 | 56ICY76AZITHROMYCIN (MACAROLIDES) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/17/2018 | 64RDY18HUMAN GROWTH HORMONE (HORMONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/19/2018 | 65JCK21MEDROXYPROGESTERONE ACETATE (PROGESTIN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/7/2017 | 65PCY02SILDENAFIL CITRATE (REGULATOR) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/24/2017 | 64GCA99ESTROGEN N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/19/2017 | 61LCA99ANTI-COAGULANT, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/30/2017 | 61JCA08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/27/2017 | 62ODA05RAMIPRIL (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/21/2017 | 62ODA05RAMIPRIL (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/20/2016 | 62GCB41IBUPROFEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/9/2016 | 65PCY02SILDENAFIL CITRATE (REGULATOR) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/25/2016 | 63NCA23ACETYLCHOLINE CHLORIDE (CHOLINERGIC) | 75UNAPPROVED | Los Angeles District Office (LOS-DO) |
| 5/28/2015 | 66VCY99MISCELLANEOUS PATENT MEDICINES, ETC. | 179AGR RX | Cincinnati District Office (CIN-DO) |
| 9/26/2014 | 62IAY97VALRUBICIN (ANTI-NEOPLASTIC) | Division of Northeast Imports (DNEI) | |
| 7/23/2013 | 79GEMGAUZE, ABSORBABLE | New York District Office (NYK-DO) | |
| 9/11/2012 | 66SCA27NIFEDIPINE (VASODILATOR) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 6/15/2012 | 66MCK83HYDROXYZINE HCL (TRANQUILIZER) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/30/2012 | 61JCA08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/20/2012 | 56ECB20DOXYCYCLINE (TETRACYCLINES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/15/2012 | 60LDB83CELECOXIB (ANALGESIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/28/2011 | 65PDA02SILDENAFIL CITRATE (REGULATOR) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/13/2011 | 62UBK11DEXTROMETHORPHAN HYDROBROMIDE (ANTI-TUSSIVE/COLD) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 10/17/2011 | 61JDA08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC) | 179AGR RX | Florida District Office (FLA-DO) |
| 8/19/2011 | 56BJY03AMOXICILLIN TRIHYDRATE (PENICILLIN, SYNTHETICALLY PRODUCED) | Cincinnati District Office (CIN-DO) | |
| 3/28/2011 | 65KCK08LATANOPROST (PROSTAGLANDIN) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 1/6/2011 | 61NDY78SERTRALINE HYDROCHLORIDE (ANTI-DEPRESSANT) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 7/31/2009 | 61TBA28ONDANSETRON HYDROCHLORIDE (ANTI-EMETIC/NAUSEANT) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 5/24/2009 | 62ICH99ANTI-NEOPLASTIC N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 5/24/2009 | 62ICH99ANTI-NEOPLASTIC N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 10/2/2007 | 66NDP05ZIPRASIDONE HCI (TRANQUILIZER (ANTI-PSYCHOTIC) - PART II)) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 10/2/2007 | 66NDP05ZIPRASIDONE HCI (TRANQUILIZER (ANTI-PSYCHOTIC) - PART II)) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 7/31/2007 | 61JDB08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 5/2/2007 | 61WCP45FLUCONAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/6/2007 | 56YCR99ANTIBIOTIC N.E.C. | 179AGR RX | New Orleans District Office (NOL-DO) |
| 10/11/2006 | 64BCA24FUROSEMIDE (DIURETIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 8/2/2006 | 61JDB08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 11/16/2005 | 61JDB08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 9/8/2005 | 61JCA08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC) | 179AGR RX | New Orleans District Office (NOL-DO) |
| 1/7/2005 | 65PCA02SILDENAFIL CITRATE (REGULATOR) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 1/6/2005 | 62GCP99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/27/2004 | 62GDY99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | New York District Office (NYK-DO) |
| 8/11/2003 | 65PDB02SILDENAFIL CITRATE (REGULATOR) | 179AGR RX | Cincinnati District Office (CIN-DO) |
| 11/27/2002 | 65PDB02SILDENAFIL CITRATE (REGULATOR) | 179AGR RX | Cincinnati District Office (CIN-DO) |
| 3/22/2002 | 66V99MISCELLANEOUS PATENT MEDICINES, ETC. | 179AGR RX | Cincinnati District Office (CIN-DO) |
Frequently Asked Questions
What is Pfizer Inc.'s FDA import refusal history?
Pfizer Inc. (FEI: 2416101) has 74 FDA import refusal record(s) in our database, spanning from 3/22/2002 to 12/15/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Pfizer Inc.'s FEI number is 2416101.
What types of violations has Pfizer Inc. received?
Pfizer Inc. has been cited for 7 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Pfizer Inc. come from?
All FDA import refusal data for Pfizer Inc. is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.